I-Mab and ABL Bio Report Preliminary Efficacy of PD-L1/4-1BB Bispecific

Shanghai I-Mab reported positive early results from a US/Korea Phase I trial of a novel PD-L1 x 4-1BB bispecific antibody as a second-line therapy for solid tumors that were resistant to PD-(L)1 therapies. The bispecific, developed by ABL Bio of South Korea, is a combination of I-Mab’s TJ-L14B and ABL’s ABL503. Its PD-L1 arm is a tumor-dependent T-cell activator, while the 4-1BB arm activates T cells after binding the PD-(L)1 target. At a low dose, TJ-L14B/ABL produced one complete response and three partial response in 14 patients. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues: